© 2002 by Oxford University Press
Journal of the National Cancer Institute, Vol. 94, No. 1, 12-14,
January 2, 2002
© 2002 Oxford University Press
NEWS |
Heat Shock Protein Vaccine: Producing an Immune Response in Mice and Men
Pramod Srivastava, Ph.D., believes in paying attention to mice. And mice give him a lot of confidence that his heat shock protein vaccine should work in humans.
| |||||||||||
This is not just wishful thinking. Srivastava, an immunologist at the University of Connecticut School of Medicine in Farmington, has done the hard science over the last 20 years to show that the vaccine works by an identical mechanism in both mice and humans.
In preclinical studies, the vaccine protected an overwhelming majority of mice from the recurrence of cancers. Although the human phase III trials of his vaccine are not complete, so far the data are consistent with the data from mouse studies.
"Were seeing what seems like clinical activity," Srivastava said of the studies in humans. In early,
Background